Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single-Dose Vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the launch1 of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark's Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa®2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253].

According to IQVIA® sales data for the 12-month period ending May 2026, the Zyprexa® IntraMuscular Injection market3 achieved annual sales of approximately $25.4 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 2270.45 as compared to the previous close of Rs. 2209.85. The total number of shares traded during the day was 30046 in over 2352 trades.

The stock hit an intraday high of Rs. 2276.30 and intraday low of 2220.75. The net turnover during the day was Rs. 67756455.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USALaunch Olanzapine Injection